AnaptysBio CMO exercises options and sells 1,500 shares

AnaptysBio, Inc.'s Chief Medical Officer reported an equity transaction involving company stock.

Rhea-AI Filing Summary

AnaptysBio, Inc.'s Chief Medical Officer reported an equity transaction involving company stock. On 12/22/2025, the officer exercised 1,500 employee stock options at an exercise price of $18.50 per share and acquired the same number of common shares. On the same date, the officer sold 1,500 shares of common stock at a price of $50.00 per share. After these transactions, the officer directly owned 26,967 shares of AnaptysBio common stock and held 83,500 stock options from the reported grant.

The filing notes that the sale was made under a Rule 10b5-1 trading plan adopted on April 14, 2025, which is a pre-arranged plan for trading shares. It also states that the reported stock option is fully vested and that the officer holds additional options to purchase up to an aggregate of 394,810 shares of common stock, which vest according to their terms.

Insider Trade Summary

Exercise and Sale: 1,500 shares ($47K approx. pre-tax spread)

Exercise and Sale 3 txns

Insider Lizzul Paul F.

Role Chief Medical Officer

Sold 1,500 shs ($75K)

Approx. gross sale proceeds $75K

Approx. exercise cost $28K

Approx. pre-tax spread $47K

Type	Security	Shares	Price	Value
Exercise	Employee Stock Option (right to buy)	1,500	$0.00	$0.00
Exercise	Common Stock	1,500	$18.50	$28K
Sale	Common Stock	1,500	$50.00	$75K

Holdings After Transaction: Employee Stock Option (right to buy) — 83,500 contracts (Direct); Common Stock — 26,967 shares (Direct)

Footnotes (4)

1. F1. Includes the acquisition of 1,324 shares acquired under the Company's ESPP.
2. F2. The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2025.
3. F3. The stock option is fully vested.
4. F4. In addition to the remaining options to purchase 83,500 shares of common stock as set forth in Table II, the Reporting Person also holds additional options to purchase up to an aggregate of 394,810 shares of common stock, which options vest according to their terms.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did AnaptysBio (ANAB) disclose for its Chief Medical Officer?

The Chief Medical Officer exercised 1,500 employee stock options at $18.50 per share and sold 1,500 shares of common stock at $50.00 per share on 12/22/2025.

How many AnaptysBio (ANAB) shares does the reporting officer own after the transaction?

Following the reported transactions, the officer directly owned 26,967 shares of AnaptysBio common stock.

Was the AnaptysBio (ANAB) insider sale made under a Rule 10b5-1 plan?

Yes. The filing states that the sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 14, 2025.

What stock options are reported for the AnaptysBio (ANAB) Chief Medical Officer?

The officer exercised 1,500 employee stock options at $18.50 and, after the transaction, held 83,500 options from the reported grant, which is fully vested.

Does the AnaptysBio (ANAB) officer hold additional unexercised stock options?

Yes. In addition to the remaining 83,500 options in Table II, the officer also holds options to purchase up to an aggregate of 394,810 shares of common stock, which vest according to their terms.

What is the relationship of the reporting person to AnaptysBio (ANAB)?

The reporting person is an officer of AnaptysBio, Inc., serving as the company’s Chief Medical Officer.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 12/23/2025 - 04:28 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Lizzul Paul F.

(Last) (First) (Middle)

C/O ANAPTYSBIO, INC.

10770 WATERIDGE CIRCLE, SUITE 210

(Street)

SAN DIEGO CA 92121

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ANAPTYSBIO, INC [ ANAB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

3. Date of Earliest Transaction (Month/Day/Year)
12/22/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	12/22/2025		M		1,500	A	$18.5	28,467(1)	D
Common Stock	12/22/2025		S(2)		1,500	D	$50	26,967	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (right to buy)	$18.5	12/22/2025		M			1,500	(3)	07/29/2030	Common Stock	1,500	$0	83,500(4)	D

Explanation of Responses:

1. Includes the acquisition of 1,324 shares acquired under the Company's ESPP.

2. The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2025.

3. The stock option is fully vested.

4. In addition to the remaining options to purchase 83,500 shares of common stock as set forth in Table II, the Reporting Person also holds additional options to purchase up to an aggregate of 394,810 shares of common stock, which options vest according to their terms.

	/s/ Eric Loumeau, Attorney-in-Fact	12/23/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.